Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 studyRAFFI, Francois; RACHLIS, Anita; ALMOND, Steve et al.Lancet (British edition). 2013, Vol 381, Num 9868, pp 735-743, issn 0140-6736, 9 p.Article

The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapyKAUFMANN, Gilbert R; BLOCH, Mark; FINLAYSON, Robert et al.AIDS (London). 2002, Vol 16, Num 3, pp 359-367, issn 0269-9370Article

Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adultsCOHEN, Calvin; WOHL, David; WHITE, Kirsten et al.AIDS (London). 2014, Vol 28, Num 7, pp 989-997, issn 0269-9370, 9 p.Article

A Randomized Study of Pharmacokinetics, Efficacy, and Safety of 2 Raltegravir Plus Atazanavir Strategies in ART-Treated AdultsCAREY, Dianne; PETT, Sarah L; BLOCH, Mark et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 60, Num 2, pp 143-149, issn 1525-4135, 7 p.Article

Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoirKOELSCH, Kersten K; BOESECKE, Christoph; EMERY, Sean et al.AIDS (London). 2011, Vol 25, Num 17, pp 2069-2078, issn 0269-9370, 10 p.Article

Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapyWINSTON, Alan; BLOCH, Mark; CARR, Andrew et al.Journal of antimicrobial chemotherapy (Print). 2005, Vol 56, Num 2, pp 380-387, issn 0305-7453, 8 p.Article

Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. CommentaryGANDHI, Rajesh Tim; ALTFELD, Marcus; TSOUKAS, Christos et al.The Journal of infectious diseases. 2005, Vol 192, Num 4, pp 556-559, issn 0022-1899, 15 p.Article

Skeletal Muscle Toxicity Associated With Raltegravir-Based Combination Antiretroviral Therapy in HIV-Infected AdultsLEE, Frederick J; AMIN, Janaki; BLOCH, Mark et al.Journal of acquired immune deficiency syndromes (1999). 2013, Vol 62, Num 5, pp 525-533, issn 1525-4135, 9 p.Article

Adherence to HIV Treatment Guidelines for Comorbid Disease Assessment and Initiation of Antiretroviral TherapyBLOCH, Mark; HOY, Jennifer; CUNNINGHAM, Nicola et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 59, Num 5, pp 478-488, issn 1525-4135, 11 p.Article

Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trialMARTIN, Allison; AMIN, Janaki; COOPER, David A et al.AIDS (London). 2010, Vol 24, Num 17, pp 2657-2663, issn 0269-9370, 7 p.Article

Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine: A Randomized, 96-Week TrialMARTIN, Allison; BLOCH, Mark; AMIN, Janaki et al.Clinical infectious diseases. 2009, Vol 49, Num 10, pp 1591-1601, issn 1058-4838, 11 p.Article

Virologic Determinants of Success After Structured Treatment Interruptions of Antiretrovirals in Acute HIV-1 InfectionLEWIN, Sharon R; MURRAY, John M; COOPER, David A et al.Journal of acquired immune deficiency syndromes (1999). 2008, Vol 47, Num 2, pp 140-147, issn 1525-4135, 8 p.Article

Therapeutic drug monitoring of atazanavir : surveillance of pharmacotherapy in the clinicRAY, John E; MARRIOTT, Debbie; BLOCH, Mark T et al.British journal of clinical pharmacology. 2005, Vol 60, Num 3, pp 291-299, issn 0306-5251, 9 p.Article